Patents Assigned to Interlude Biopharma Co.
  • Compositions and methods for treating Sjogren's syndrome
    Patent number: 12414979
    Abstract: The present invention provides compositions and methods for treating Sjogren's syndrome (SS), including primary or secondary SS, as well as methods for preventing clinical disease in patients at risk of developing clinical SS. In various embodiments, the invention relates to administering a regimen of larazotide (or derivative) and/or 4-APAA compounds or 5-ASA compounds (e.g., 5-ASA, 4-ASA, 4-Ac APAA, and 4-APAA) to a patient in need thereof.
    Type: Grant
    Filed: November 3, 2021
    Date of Patent: September 16, 2025
    Assignees: Interlude Biopharma Co., Oklahoma Medical Research Foundation
    Inventors: Jay P. Madan, Kathy L. Sivils, Umesh Deshmukh, Balasingham Radhakrishnan, Kendyle Kennsengten, Harini Bagavant
  • Larazotide formulations
    Patent number: 12337024
    Abstract: The present invention provides, in part, compositions comprising a peptide that is larazotide or larazotide derivative, or salt thereof, contained within a matrix that provides for controlled release and sustained release formulations. The present invention contemplates that these compositions, formulations and methods can be useful for treating diseases and disorders of the small bowel.
    Type: Grant
    Filed: August 14, 2020
    Date of Patent: June 24, 2025
    Assignee: Interlude Biopharma Co.
    Inventors: Balasingham Radhakrishnan, Jay P. Madan, Gary F. Musso